Development of Highly Sensitive Biosensors of RAF Dimerization in Cells

Area of Science:

• Biochemistry
• Molecular Biology
• Oncology

Background:

• BRAF inhibitors like dabrafenib and vemurafenib show clinical success in BRAF-mutated melanomas.
• Adverse events including drug resistance and secondary tumors are linked to RAF dimerization induced by these inhibitors.
• Developing safer BRAF inhibitors requires understanding and monitoring RAF dimerization.

Purpose of the Study:

• To develop a sensitive biosensor for detecting RAF dimerization in cells.
• To utilize the split enhanced click beetle luciferase (Emerald Luc, ELuc) complementation technique for this purpose.
• To enable high-throughput screening of RAF inhibitors based on their dimerization-inducing potential.

Main Methods:

• Development of a novel biosensor system using split Emerald Luc (ELuc) complementation.
• Application of the biosensor for high-throughput screening in a microplate format.
• Comprehensive analysis of commercially available RAF inhibitors for their RAF dimerization potency.

Main Results:

• The developed biosensor system effectively detects RAF dimerization in cellular contexts.
• The system is suitable for high-throughput screening of RAF inhibitors.
• Commercially available RAF inhibitors display varying potencies in inducing RAF dimerization, which do not consistently correlate with enzyme inhibition.

Conclusions:

• A sensitive and effective biosensor for RAF dimerization has been established.
• This assay system can differentiate RAF inhibitors based on their dimerization-inducing effects.
• The tool is poised to facilitate the discovery of next-generation BRAF inhibitors with improved safety profiles.